| |
No. of events
|
No. of participants
|
Model 1
|
Model 2
|
Model 3
|
P trend
|
|---|
|
Tertile 1
|
108
|
274
|
Ref.
|
Ref.
|
Ref.
|
< 0.001
|
|
Tertile 2
|
56
|
274
|
0.46 (0.33–0.64)
|
0.47 (0.34–0.66)
|
0.46 (0.33–0.64)
|
|
Tertile 3
|
27
|
274
|
0.23 (0.15–0.35)
|
0.24 (0.15–0.37)
|
0.24 (0.16–0.38)
|
|
Age, years
|
|
< 60
|
|
Tertile 1
|
26
|
76
|
Ref.
|
Ref.
|
Ref.
|
< 0.001
|
|
Tertile 2
|
20
|
121
|
0.40 (0.22–0.72)
|
0.55 (0.30–1.01)
|
0.55 (0.30–1.01)
|
|
Tertile 3
|
14
|
163
|
0.21 (0.11–0.40)
|
0.28 (0.14–0.56)
|
0.29 (0.15–0.59)
| |
|
≥ 60
|
|
Tertile 1
|
82
|
198
|
Ref.
|
Ref.
|
Ref.
|
< 0.001
|
|
Tertile 2
|
36
|
153
|
0.49 (0.33–0.73)
|
0.47 (0.31–0.70)
|
0.46 (0.31–0.70)
|
|
Tertile 3
|
13
|
111
|
0.24 (0.13–0.44)
|
0.23 (0.12–0.41)
|
0.23 (0.13–0.43)
|
- Model 1 adjusted for age and gender; Model 2 further adjusted for Model 1 puls primary prevention, NYHA, CRT-D, LVEF, LVEDD, β-blockers, and aldosterone antagonists; Model 3 adjusted factors in Model 2 and potential mediators on the causal pathway including BMI, ischemic cardiomyopathy, hypertension, AF, diabetes, prior myocardial infarction
